Differences in verapamil response between CYP3A5 genotypes.

被引：1
|
作者：
Langaee, TY
Yarandi, HN
Katz, DA
Dehoff, RM
Kehoe, JM
Klocman, AS
Pepine, CJ
Johnson, JA
机构：
[1] Univ Florida, Gainesville, FL USA
[2] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2006年 / 79卷 / 02期
关键词：
D O I：
10.1016/j.clpt.2005.12.043
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P12 / P12
页数：1
相关论文
共 50 条
  • [21] PHARMACOKINETICS OF CIPROFLOXACIN IN ASIANS WITH DIFFERENT CYP2C19 AND CYP3A5 GENOTYPES
    Zhao, Bin
    Moochhala, Shabbir
    Lu, Jia
    Yap, Eric
    Goh, Boon Cher
    Lee, How Sung
    Lai, Mui Hoon
    Tan, Lili
    CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2005, 58 : 35 - 35
  • [22] Differences in Tacrolimus Troughs and Doses Between Caucasians and African Americans with Two CYP3A5 Loss-of-Function Alleles: Looking Beyond CYP3A5 Expression.
    Oetting, W.
    Schladt, D.
    Guan, W.
    Remmel, R.
    Dorr, C.
    Sanghavi, K.
    Matas, A.
    Mannon, R.
    Israni, A.
    Jacobson, P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 : 681 - 682
  • [23] Association Between CYP3A5☆1 and CYP3A5☆3 Polymorphisms, With the Formation of ADES and the Presence of Rejection in Renal Transplant Recipients
    Garcia, Luis
    Quintanilla, Alan
    Hinojosa, Hector
    Vargas, Lionel
    Fernandez, Diana
    Garcia, Aldo
    TRANSPLANTATION, 2022, 106 (09) : S275 - S275
  • [24] Association between CYP3A5 genotypes with hypertension in Chinese Han population: A case-control study
    Li, Zhanzhan
    Chen, Peng
    Zhou, Tao
    Chen, Xiaofang
    Chen, Lizhang
    CLINICAL AND EXPERIMENTAL HYPERTENSION, 2017, 39 (03) : 235 - 240
  • [25] Interactions Between CYP3A5*3 and POR*28 Polymorphisms and Lipid Lowering Response with Atorvastatin
    Wei, Kan-kan
    Zhang, Li-rong
    CLINICAL DRUG INVESTIGATION, 2015, 35 (09) : 583 - 591
  • [26] CYP3A5 polymorphism is associated with differences on gene expression and cholesterol-lowering response to atorvastatin
    Willrich, M. V.
    Hirata, M. H.
    Bernik, M. M.
    Dorea, E. L.
    Bertolami, M. C.
    Faludi, A.
    Hirata, R. D.
    CLINICAL CHEMISTRY, 2007, 53 (06) : A151 - A151
  • [27] Association between the CYP3A5 genotype and blood pressure
    Ho, H
    Pinto, A
    Hall, SD
    Flockhart, DA
    Li, L
    Skaar, TC
    Cadman, P
    O'Connor, DT
    Wagner, U
    Fineberg, NS
    Weinberger, MH
    HYPERTENSION, 2005, 45 (02) : 294 - 298
  • [28] Interactions Between CYP3A5*3 and POR*28 Polymorphisms and Lipid Lowering Response with Atorvastatin
    Kan-kan Wei
    Li-rong Zhang
    Clinical Drug Investigation, 2015, 35 : 583 - 591
  • [29] Effect of CYP3A4*22 and CYP3A5 Combined Genotypes on Tacrolimus Disposition in Heart Transplantation
    Vu, A.
    Page, R. L.
    Roscoe, N.
    Lindenfeld, J. A.
    Aquilante, C. L.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2014, 33 (04): : S115 - S116
  • [30] CYP3A5 genotypes and risk of oesophageal cancer in two South African populations
    Dandara, C
    Ballo, R
    Parker, MI
    CANCER LETTERS, 2005, 225 (02) : 275 - 282
12345